IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candid…
Biotechnology
US, South San Francisco [HQ]
Ratios
7 Sheets · From 2023 to 2017Configuration
Margins, Growth Rates In %
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross Margin | - - | - - | - - | -103.18 | 93.83 | 95.87 | 82.86 | |
| Profit Margin | - - | - - | - - | -165.14 | -170.11 | -107.61 | -483.05 | |
| Operating Margin | - - | - - | - - | -180.90 | -179.91 | -122.72 | -574.85 | |
|
EPS Growth
|
- - | -190.36 | 21.16 | 31.05 | -3.05 | 2.22 | -48.49 | |
| EPS USD | -83.00 | -241.00 | -190.00 | -131.00 | -135.00 | -132.00 | -196.00 | |
| Return on Assets (ROA) | -67.86 | -35.58 | -34.02 | -10.82 | -12.46 | -14.13 | -17.40 | |
| Return on Equity (ROE) | 75.37 | 70.17 | -38.29 | -16.27 | -15.76 | -15.68 | -18.19 | |
| Return on Invested Capital (ROIC) | 90.57 | 78.89 | -37.83 | -16.13 | -15.66 | -16.55 | -21.54 | |
| Solvency | ||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | - - | 5.99 | 2.25 | 1.36 | 0.90 | 0.44 | |
| Debt/Equity | - - | - - | 6.75 | 3.39 | 1.72 | 1.00 | 0.46 | |
| Debt/EBITDA | 42.44 | 57.71 | 61.65 | 184.80 | 172.80 | 104.24 | 118.19 | |
|
Debt/Capitalization
|
- - | - - | 6.32 | 3.28 | 1.69 | 0.99 | 0.46 | |
| Long-Term Debt/Capitalization | - - | - - | 5.31 | 2.55 | 1.14 | 0.46 | 0.18 | |
| Interest Debt per Share USD | - - | - - | 0.33 | 0.31 | 0.15 | 0.18 | 0.42 | |
| Debt Growth | - - | - - | - - | -0.72 | -22.94 | -32.79 | -17.52 | |
| Liquidity | ||||||||
| Current Ratio | 557.76 | 1,674.99 | 1,447.87 | 746.91 | 555.81 | 1,167.96 | 1,965.36 | |
| Quick Ratio | 540.55 | 1,661.94 | 1,425.88 | 738.77 | 548.89 | 1,150.89 | 1,937.68 | |
| Cash Ratio | 244.91 | 378.81 | 490.88 | 186.43 | 203.83 | 216.38 | 579.38 | |
| Operating Cash Flow Ratio | -500 | -500 | -500 | 100 | -100 | -200 | -400 | |
| Turnover | ||||||||
| Inventory Turnover | - - | - - | - - | - - | -1.42 | -25.26 | 0.75 | |
| Receivables Turnover | - - | - - | - - | 1,040.92 | 2,533.18 | 24,137.92 | 129,916.67 | |
| Payables Turnover | - - | - - | 175.60 | 4,165.58 | 82.14 | 49.09 | 60.75 | |
|
Asset Turnover
|
- - | - - | - - | 6.55 | 7.33 | 13.13 | 3.60 | |
| Fixed Turnover | - - | - - | - - | 206.18 | 322.61 | 566.34 | 278.06 | |
| Coverage | ||||||||
| Interest Coverage | - - | - - | - - | -4,163.02 | - - | -1,624.69 | -626.18 | |
| Asset Coverage | - - | - - | 1,500 | 3,800 | 6,500 | 10,200 | 21,700 | |
| Cash Flow Coverage (CFGR) | - - | - - | -580.52 | 824.97 | -1,076.61 | -2,503.59 | -4,011.98 | |
| EBITDA Coverage | - - | - - | - - | -4,100 | - - | -1,600 | -600 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -7.44 | -21.55 | -25.33 | -9.32 | -5.70 | -7.28 | -5.52 | |
|
Price/Earnings (P/E)
|
-1,343.41 | -463.97 | -394.75 | -1,072.69 | -1,753.31 | -1,373.98 | -1,811.74 | |
| Price/Earnings Growth (PEG) | - - | -2.44 | 18.65 | 34.54 | -574.21 | 618.29 | -37.37 | |
|
Price/Book (P/B)
|
-1,012.49 | -325.56 | 151.15 | 174.56 | 276.39 | 215.49 | 329.51 | |
| Price/Tangible Book (P/TB) | -1,012.49 | -325.56 | 151.15 | 174.56 | 276.39 | 215.49 | 329.51 | |
| Price/Sales (P/S) | - - | - - | - - | 1,771.44 | 2,982.60 | 1,478.57 | 8,751.59 | |
|
Price/Cash Flow (P/CF)
|
-1,303.63 | -576.96 | -386.01 | 624.03 | -1,494.05 | -863.84 | -1,776.16 | |
| Price/Free CF (P/FCF) | -1,139.80 | -543.36 | -373.16 | 629.62 | -1,426.44 | -831.02 | -1,740.39 | |
| Price/Operating CF (P/OCF) | -1,303.63 | -576.96 | -386.01 | 624.03 | -1,494.05 | -863.84 | -1,776.16 |